RTCA Human

RNA 3'-Terminal Phosphate Cyclase Human Recombinant
Shipped with Ice Packs
In Stock

Description

Enzymatic Mechanism

RTCA operates via a three-step catalytic cycle:

  1. Adenylylation: ATP reacts with His320 to form a covalent RtcA-AMP intermediate.

  2. Phosphate Transfer: AMP is transferred to the RNA 3'-phosphate, generating RNA(3')pp(5')A.

  3. Cyclization: The vicinal 2'-OH attacks the 3'-phosphorus, yielding a 2',3'-cyclic phosphate .

Structural studies reveal adenine binding in a hydrophobic pocket (Tyr284, Pro131, Phe135), enforcing ATP specificity. The ribose O2' and O3' form hydrogen bonds with Arg86, Arg146, and Arg150, ensuring ribonucleotide selectivity .

Substrate Specificity and Novel Activity

While RTCA primarily targets 3'-phosphates, recent studies demonstrate its ability to cyclize 2'-phosphates at a rate ~10⁵ slower than 3'-phosphates. Binding affinity (Kd) for 2'-phosphate RNA is comparable to 3'-phosphate RNA, suggesting phosphate geometry—not binding—dictates kinetics .

SubstrateCatalytic Rate (kcat)Binding Affinity (Kd)
RNA 3'-phosphate1.0 min⁻¹25 nM
RNA 2'-phosphate1.4 × 10⁻⁵ min⁻¹30 nM

This dual activity implies potential roles in repairing RNA damaged by ribotoxins or oxidative stress .

Research Applications

RTCA Human Recombinant (PRO-2003) is widely used to:

  • Study RNA repair pathways in vitro .

  • Investigate enzyme kinetics and inhibitor development .

  • Explore crosstalk with RNA ligase RtcB, which processes RTCA-generated cyclic phosphates during tRNA splicing .

Key Synonyms and Database References

SynonymSource
RNA terminal phosphate cyclase domain-containing protein 1UniProt
RTC1PMC
RNA cyclaseProspec Bio

Product Specs

Introduction
RNA 3'-Terminal Phosphate Cyclase (RTCA) is a member of the RNA 3'-phosphate cyclase family. This protein plays a role in RNA metabolism by catalyzing the conversion of the 3'-phosphate of RNA substrates to a 2',3'-cyclic phosphodiester in a reaction that requires ATP. RTCA is involved in specific stages of cellular RNA processing.
Description
Recombinant human RTCA protein was expressed in E. coli and purified to a single, non-glycosylated polypeptide chain. It encompasses amino acids 1-366 and has a molecular weight of 41.7 kDa. The protein includes a 23 amino acid His-tag fused at the N-terminus. Purification was achieved using proprietary chromatographic techniques.
Physical Appearance
The product is a sterile, colorless solution that has been filtered.
Formulation
The RTCA protein is supplied in a solution at a concentration of 0.25 mg/ml. The solution also contains 20 mM Tris-HCl buffer (pH 8.0), 0.15 M NaCl, 20% glycerol, and 1 mM DTT.
Stability
For short-term storage (up to 2-4 weeks), the product can be stored at 4°C. For longer storage, it is recommended to freeze the product at -20°C. To ensure stability during long-term storage, adding a carrier protein (0.1% HSA or BSA) is advisable. Avoid repeated freezing and thawing of the product.
Purity
The purity of the RTCA protein is greater than 85.0% as determined by SDS-PAGE analysis.
Synonyms
RNA 3'-terminal phosphate cyclase, RPC, RTC1, RTCD1, RNA cyclase, RNA-3'-phosphate cyclase, RNA terminal phosphate cyclase domain-containing protein 1, RTC domain-containing protein 1, RTCA, RPC1.
Source
Escherichia Coli.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MGSMAGPRVE VDGSIMEGGG QILRVSTALS CLLGLPLRVQ KIRAGRSTPG LRPQHLSGLE MIRDLCDGQL EGAEIGSTEI TFTPEKIKGG IHTADTKTAG SVCLLMQVSM PCVLFAASPS ELHLKGGTNA EMAPQIDYTV MVFKPIVEKF GFIFNCDIKT RGYYPKGGGE VIVRMSPVKQ LNPINLTERG CVTKIYGRAF VAGVLPFKVA KDMAAAAVRC IRKEIRDLYV NIQPVQEPKD QAFGNGNGII IIAETSTGCL FAGSSLGKRG VNADKVGIEA AEMLLANLRH GGTVDEYLQD QLIVFMALAN GVSRIKTGPV TLHTQTAIHF AEQIAKAKFI VKKSEDEEDA AKDTYIIECQ GIGMTNPNL.

Q&A

What is the RTCA approach to human factors in aviation systems?

The RTCA approach to human factors is based on an integrated learning methodology that emphasizes proactive consideration of human capabilities and limitations throughout the design and certification process. The approach demonstrates how human factors engineering contributes to safe and effective flight deck design through a practical application of human factors principles. RTCA has developed standard DO-372, "Addressing Human Factors/Pilot Interface Issues for Avionics," which serves as a foundation for applying human factors in aviation contexts. This standard utilizes real-world examples and lessons learned to inform the development and certification process .

What core human performance aspects are addressed in RTCA human factors guidance?

RTCA human factors guidance addresses several critical aspects of human performance including:

  • Physical and physiological capabilities of flight crews

  • Cognitive performance limitations

  • Impact of systemic variables in the flight deck environment on crew performance

  • Factors affecting crew workload

  • Human error mechanisms and mitigation strategies

  • User-centered design methodologies

This comprehensive approach ensures that human capabilities and limitations are considered during the design and certification of aviation systems.

How can researchers incorporate total systems safety approaches when applying RTCA human factors principles?

Researchers should implement a holistic methodology that:

  • Designs systems specifically to support human performance rather than expecting humans to adapt to system limitations

  • Recognizes the limitations of regulatory compliance as the sole design approach

  • Develops a culture that prioritizes human performance considerations throughout design and certification processes

  • Utilizes cross-disciplinary approaches involving engineers, human factors specialists, and operational experts4

The implementation of this approach requires systematic evaluation of how design decisions affect human performance across various operational scenarios, integrating quantitative and qualitative assessments that go beyond minimum regulatory requirements.

What methodologies does RTCA recommend for evaluating human-system integration in complex flight systems?

RTCA recommends a multi-method evaluation strategy that includes:

Evaluation MethodApplication StagePrimary MeasuresLimitations
Engineering AnalysisEarly designTask completion, workload estimatesLimited ecological validity
Simulation-Based AssessmentMid-designPerformance metrics, situation awarenessSimulation fidelity constraints
Human-in-the-Loop TestingLate designWorkload, error rates, usability metricsResource intensive
Operational EvaluationPre-certificationReal-world performance, user acceptanceLimited control of variables

This progressive evaluation approach ensures that human factors issues are identified early when changes are less costly, while still validating the final design under representative conditions .

What advanced approaches can researchers use to manage contradictions between certification requirements and optimal human factors design?

Researchers should employ a structured methodology to address these contradictions:

  • Identify the specific regulatory requirements that appear to conflict with human factors principles

  • Document the human performance implications using objective evidence from testing

  • Develop alternative design solutions that satisfy both regulatory intent and human factors principles

  • Engage certification authorities early with data-driven rationales for alternative means of compliance

  • Utilize the "equivalent level of safety" provision where appropriate to implement human-centered designs that may not strictly follow prescriptive requirements but achieve safety objectives

This approach requires thorough documentation of the design rationale and supporting evidence demonstrating how the alternative solution maintains or improves safety.

What are the fundamental principles behind Real-Time Cell Analysis (RTCA) technology?

RTCA is a label-free technology that enables continuous monitoring of cell behavior through impedance measurements. The system detects changes in electrical impedance as cells attach, proliferate, or change morphology on electrode-containing plates. This allows for real-time, quantitative assessment of cellular responses without the need for endpoint measurements or cellular labeling. The technology provides continuous data on cell adhesion, morphology changes, and proliferation rates, offering advantages over traditional endpoint assays that only capture single time points .

What types of human cell parameters can be effectively monitored using RTCA systems?

RTCA systems can monitor multiple cell parameters simultaneously:

ParameterMeasurement PrincipleApplications
Cell ProliferationImpedance increases as cells divide and cover electrodesDrug screening, toxicity testing
Cell AdhesionChanges in contact between cells and electrodesMetastasis research, compound effects
Morphology ChangesSubtle alterations in cell shape affect impedanceCytotoxicity, virus-induced effects
Barrier FunctionImpedance in epithelial/endothelial monolayersTransport studies, barrier integrity
Migration/InvasionCells moving through a membraneMetastasis research, wound healing
CytotoxicityDeclining impedance with cell deathDrug screening, toxicology

These parameters can be tracked in real-time throughout an entire experiment, providing rich temporal data on cellular responses .

How can researchers optimize RTCA experimental designs to detect subtle cytotoxic effects of compounds on human cells?

Researchers should implement the following optimization strategies:

  • Establish stable baseline measurements before compound addition (minimum 24 hours) to account for normal growth patterns

  • Determine optimal seeding density through preliminary experiments as this significantly affects signal-to-noise ratio

  • Include appropriate positive and negative controls in each plate to normalize for plate-to-plate variations

  • Use multiple concentrations with narrow intervals around expected effect thresholds to precisely determine IC50 values

  • Extend monitoring periods to capture delayed cytotoxic effects that may be missed in standard endpoint assays

  • Normalize cell index data to the time point immediately before treatment to isolate treatment effects from growth differences

  • Combine RTCA with endpoint assays to correlate impedance changes with specific cellular mechanisms (apoptosis, necrosis, etc.)

This methodology has been successfully applied in studies of plant extracts, drug screening, and environmental toxicology to detect subtle effects that traditional methods might miss.

What methodological approaches help resolve contradictory results between RTCA and traditional endpoint assays?

When facing contradictions between RTCA and traditional assays, researchers should:

  • Compare the temporal dynamics of cellular responses in RTCA with the specific time points of endpoint assays

  • Evaluate whether changes in cell morphology rather than viability might explain RTCA results

  • Investigate potential interference of test compounds with the impedance measurements (false positives)

  • Analyze whether endpoint assay reagents may interact with test compounds (false negatives)

  • Design time-matched experiments where cells from the same passage are analyzed in parallel with both methods

  • Consider employing a third orthogonal method to resolve discrepancies

  • Utilize microscopic imaging to correlate morphological observations with impedance measurements

Research has shown that RTCA often detects earlier responses than endpoint methods, which may explain apparent contradictions. For example, studies with plant metabolites demonstrated that RTCA could detect cytostatic effects before they manifested as reduced viability in endpoint assays.

How can RTCA technology be applied effectively in microbiological research with human pathogens?

RTCA technology offers several methodological advantages for human pathogen research:

  • Virus-induced cytopathic effect (CPE) detection:

    • Provides quantitative, real-time data on the progression of viral infections

    • Allows precise determination of when CPE begins, unlike endpoint methods

    • Enables calculation of viral titers based on time-to-CPE measurements

    • Has been successfully applied to studies of herpes simplex virus, human cytomegalovirus, human enterovirus, and other pathogens

  • Bacterial toxin detection:

    • Permits rapid quantification of toxin-induced cellular effects

    • Can detect toxins directly from clinical samples without bacterial isolation

    • Provides higher sensitivity than traditional biochemical assays

    • Has been validated for detection of Vibrio cholerae toxin and Clostridium difficile toxins

  • Antiviral/antimicrobial drug screening:

    • Enables determination of minimum inhibitory concentrations in real-time

    • Allows monitoring of time-dependent drug effects

    • Facilitates assessment of synergistic drug combinations

    • Provides data on potential cytotoxicity of candidate compounds simultaneously

This methodology significantly reduces the time required for microbiological research while providing more detailed information on infection dynamics and therapeutic interventions.

What are best practices for analyzing time-series data from RTCA systems in both aviation and cell biology contexts?

Time-series analysis of RTCA data requires structured approaches regardless of the application domain:

These methodological approaches help researchers extract meaningful insights from complex temporal data in both biological and aviation research contexts.

How should researchers design experiments to maximize the value of RTCA approaches?

Regardless of the specific RTCA application, robust experimental design principles include:

  • Control strategies:

    • Include appropriate positive and negative controls

    • Design matched controls for each experimental variable

    • Consider factorial designs to examine interaction effects

  • Replication requirements:

    • Conduct biological replicates across different batches/individuals

    • Perform technical replicates to establish measurement reliability

    • Power analyses to determine appropriate sample sizes

  • Time considerations:

    • Select appropriate sampling intervals based on expected response dynamics

    • Plan experiment duration to capture both immediate and delayed effects

    • Include recovery periods when applicable

  • Validation approaches:

    • Triangulate findings with complementary methodologies

    • Verify key findings through alternative experimental paradigms

    • Test reproducibility across different conditions or populations

Effective experimental design is essential for generating reliable and interpretable results using RTCA technologies, whether in aviation human factors research or cellular analysis applications.

Product Science Overview

Structure and Mechanism

The RNA 3’-Terminal Phosphate Cyclase operates through a multi-step mechanism :

  1. Adenylylation: The enzyme first forms a covalent intermediate with AMP (adenosine monophosphate) in the presence of ATP.
  2. Cyclization: The enzyme-AMP complex then interacts with the RNA substrate, converting the 3’-phosphate group into a 2’,3’-cyclic phosphodiester.
  3. Release: The cyclic phosphate is released, completing the reaction.

This process is essential for the maintenance of cyclic ends in tRNA splicing intermediates and the cyclization of the 3’ end of U6 snRNA .

Physiological Function

While the exact physiological role of RNA 3’-Terminal Phosphate Cyclase is not fully understood, it is believed to be involved in several critical RNA processing events :

  • tRNA Splicing: The enzyme may help maintain cyclic ends in tRNA splicing intermediates, which are crucial for proper tRNA maturation.
  • snRNA Processing: It could also play a role in the cyclization of the 3’ end of U6 snRNA, a component of the spliceosome involved in pre-mRNA splicing.
Conservation and Expression

RNA 3’-Terminal Phosphate Cyclase is highly conserved across different domains of life, including Eucarya, Bacteria, and Archaea . This conservation suggests that the enzyme performs an essential function in RNA metabolism. The enzyme is expressed in various mammalian tissues and cell lines, indicating its widespread importance .

Research and Applications

The human recombinant form of RNA 3’-Terminal Phosphate Cyclase has been extensively studied to understand its structure, function, and potential applications . Research has shown that the enzyme is nuclear and has a diffuse nucleoplasmic localization . This localization is consistent with its role in RNA processing events that occur in the nucleus.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.